FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947922406> ?p ?o ?g. }

• W2947922406 abstract "3021 Background: Pazopanib (pazo) is an oral tyrosine kinase inhibitor of VEGFR, PDGFR and c-Kit. It is a weak inhibitor of CYP3A4 and CYP2C8 and may decrease paclitaxel (P) clearance. Daily pazo with P and carboplatin (C) every 21 days was not feasible on a previous study. We hypothesized that pazo dosed intermittently and on a different day from P and C may be tolerable. We sought to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics (PK) of pazo with weekly P and C. Methods: Using a 3+3 standard design, a schedule of P 60-80 mg/m 2 and C AUC2 on days 1, 8, and 15 with pazo 400-800 mg on days 2-5, 9-12, and 16-26 on a 28-day cycle was evaluated. Pazo alone could be continued if P and C were omitted due to maximal benefit or toxicity. PK was collected during cycles 1 and 2. Results: 34 patients (pts) were treated over 6 dose levels (Table). Mean age 57 (37-79). Tumor types: breast (22), lung (3) and other (9); 27 had prior platinum. Delay in starting cycle 2 due to grade 3 neutropenia was a DLT at dose level 2 and 5. Pts on 5A missed dosing during C1 and C2 due to neutropenia and required subsequent growth factor, and this was deemed unlikely to be sustainable long-term. All grade toxicities included anemia (62%), neutropenia (59%), and thrombocytopenia (56%). Protocol-defined MTD was not determined. PK analysis showed a dose proportional increase in pazo concentration, consistent with previous reports. Pazo did not alter the PK of C. C max of P was higher C2D1 vs C1D1; mean C max ratio between C2D1:C1D1 was 1.63 (95% CI:1.29-1.96). There were 11 objective responses (3 CRs, 8 PRs). Five breast pts were on pazo alone for a median of 9 cycles (2-52) with CR (2), PR (2) and SD (1); a squamous cell of unknown primary in CR received 22 cycles. Clinical trial information: NCT01407562. Conclusions: PK confirm that pazo is a weak inhibitor of CYP3A4 and CYP2C8. Myelosuppression was a major adverse event at all dose levels. MTD was not determined. Antitumor activity was achieved with this alternate combination schedule and sustained responses from sequential pazo monotherapy was observed.[Table: see text]" @default.
• W2947922406 created "2019-06-07" @default.
• W2947922406 creator A5007972354 @default.
• W2947922406 creator A5019584569 @default.
• W2947922406 creator A5022891785 @default.
• W2947922406 creator A5034704814 @default.
• W2947922406 creator A5038468673 @default.
• W2947922406 creator A5041474007 @default.
• W2947922406 creator A5048331793 @default.
• W2947922406 creator A5053602981 @default.
• W2947922406 creator A5054371540 @default.
• W2947922406 creator A5071773606 @default.
• W2947922406 creator A5081735541 @default.
• W2947922406 creator A5090448050 @default.
• W2947922406 date "2019-05-20" @default.
• W2947922406 modified "2023-09-29" @default.
• W2947922406 title "A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors." @default.
• W2947922406 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.3021" @default.
• W2947922406 hasPublicationYear "2019" @default.
• W2947922406 type Work @default.
• W2947922406 sameAs 2947922406 @default.
• W2947922406 citedByCount "0" @default.
• W2947922406 crossrefType "journal-article" @default.
• W2947922406 hasAuthorship W2947922406A5007972354 @default.
• W2947922406 hasAuthorship W2947922406A5019584569 @default.
• W2947922406 hasAuthorship W2947922406A5022891785 @default.
• W2947922406 hasAuthorship W2947922406A5034704814 @default.
• W2947922406 hasAuthorship W2947922406A5038468673 @default.
• W2947922406 hasAuthorship W2947922406A5041474007 @default.
• W2947922406 hasAuthorship W2947922406A5048331793 @default.
• W2947922406 hasAuthorship W2947922406A5053602981 @default.
• W2947922406 hasAuthorship W2947922406A5054371540 @default.
• W2947922406 hasAuthorship W2947922406A5071773606 @default.
• W2947922406 hasAuthorship W2947922406A5081735541 @default.
• W2947922406 hasAuthorship W2947922406A5090448050 @default.
• W2947922406 hasConcept C121608353 @default.
• W2947922406 hasConcept C126322002 @default.
• W2947922406 hasConcept C143998085 @default.
• W2947922406 hasConcept C170493617 @default.
• W2947922406 hasConcept C180361614 @default.
• W2947922406 hasConcept C2775960820 @default.
• W2947922406 hasConcept C2776694085 @default.
• W2947922406 hasConcept C2777292972 @default.
• W2947922406 hasConcept C2778239845 @default.
• W2947922406 hasConcept C2778439243 @default.
• W2947922406 hasConcept C2778820342 @default.
• W2947922406 hasConcept C2779490328 @default.
• W2947922406 hasConcept C2781451048 @default.
• W2947922406 hasConcept C42362537 @default.
• W2947922406 hasConcept C71924100 @default.
• W2947922406 hasConcept C98274493 @default.
• W2947922406 hasConceptScore W2947922406C121608353 @default.
• W2947922406 hasConceptScore W2947922406C126322002 @default.
• W2947922406 hasConceptScore W2947922406C143998085 @default.
• W2947922406 hasConceptScore W2947922406C170493617 @default.
• W2947922406 hasConceptScore W2947922406C180361614 @default.
• W2947922406 hasConceptScore W2947922406C2775960820 @default.
• W2947922406 hasConceptScore W2947922406C2776694085 @default.
• W2947922406 hasConceptScore W2947922406C2777292972 @default.
• W2947922406 hasConceptScore W2947922406C2778239845 @default.
• W2947922406 hasConceptScore W2947922406C2778439243 @default.
• W2947922406 hasConceptScore W2947922406C2778820342 @default.
• W2947922406 hasConceptScore W2947922406C2779490328 @default.
• W2947922406 hasConceptScore W2947922406C2781451048 @default.
• W2947922406 hasConceptScore W2947922406C42362537 @default.
• W2947922406 hasConceptScore W2947922406C71924100 @default.
• W2947922406 hasConceptScore W2947922406C98274493 @default.
• W2947922406 hasLocation W29479224061 @default.
• W2947922406 hasOpenAccess W2947922406 @default.
• W2947922406 hasPrimaryLocation W29479224061 @default.
• W2947922406 isParatext "false" @default.
• W2947922406 isRetracted "false" @default.
• W2947922406 magId "2947922406" @default.
• W2947922406 workType "article" @default.